

IGI LABORATORIES, INC
Form 8-K
July 24, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **July 24, 2014**

IGI LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation)

001-08568
(Commission File Number)

01-0355758
(IRS Employer Identification No.)

105 Lincoln Avenue
Buena, New Jersey
(Address of principal executive
offices)

08310
(Zip Code)

Registrant's telephone number, including area code: **(856) 697-1441**

(Former name or former address, if changed since last report)

Edgar Filing: IGI LABORATORIES, INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

On July 24, 2014, Damian Finio advised IGI Laboratories, Inc. (the **Company**) that he will be resigning as a director of the Company's Board of Directors effective August 11, 2014. On July 24, 2014, the Company issued a press release announcing Mr. Finio's resignation. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01

Financial Statements and Exhibits.

(d)

The following exhibit is filed with this Report:

| Exhibit No. | Description |
|--------------------|---|
| 99.1 | Press release of IGI Laboratories, Inc. dated July 24, 2014 |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IGI LABORATORIES, INC.

Date: July 24, 2014

By: /s/ Jenniffer Collins
Name: Jenniffer Collins
Title: Chief Financial Officer